ArticleThe oncologist2013

Approval summary: Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer.

Martin H Cohen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.